Sort by
Refine Your Search
-
Listed
-
Field
-
Translational Genomics – MOSACLID (ANR 2025) & GENIAL (HORIZON EU) Projects Contract type: Fixed-term postdoctoral contract (Inserm) Duration: 12 months renewable Starting date: 2026 (1st semester) Host structure
-
Investigator of Gendhi, CESSP – CNRS UMR 8209 – EHESS – University of Paris 1 Panthéon-Sorbonne) and Maxime Bertoux (Director of the Inserm INTERACTIONS team – INTEgrative Research in Affective, CogniTIve and
-
Strasbourg on a joint project between CNRS (Team STREINTH, UMR7242, Biotechnology and Cell Signaling, ESBS) and Inserm (Group GP-SMIT, U1260, Nanomedicine, CRBS), starting in 2026. The postdoctoral project
-
the framework of the acquisition of a state-of-the-art preclinical PET-CT scanner, UMR 1240 INSERM, IMoST UCA localized in Clermont Ferrand, France, is recruiting a postdoctoral researcher to strengthen its
-
Paris, France | Institut de l’Audition (Institut Pasteur) Duration: 24 months (flexible start) Supervisor: Keith Doelling (INSERM) About the position We are recruiting a postdoctoral researcher to
-
CNRS and INSERM. It is part of an internationally recognized institution focused on cutting-edge research in computational biology, cancer, and infectious diseases. The team combines expertise from
-
analysis) approaches. Responsibilities: Under the supervision of Dr. Nicolas Marie (a CNRS researcher), the postdoctoral fellow will: Modulate SEZ6 expression in vivo (AAV, shRNA) and assess its impact on
-
Unit, UMR 8199/ U1283 CNRS, INSERM, Institut Pasteur de Lille, CHU Lille, Université Lille) in the “Metabolome, Microbiome and Metabolic Diseases” team and the metabolomic platform IMPACT-PM, directed by
-
24 Feb 2026 Job Information Organisation/Company University of Tours Department Inserm U1100 Research Field Biological sciences » Biology Researcher Profile First Stage Researcher (R1) Recognised
-
treatment using advanced mass spectrometry techniques. Impact and benefits This project could improve understanding of CAP-induced tissue remodeling and pave the way for new therapies for hepatic fibrosis